Genome-wide association study identifies genetic determinants of urine PCA3 levels in men

Neoplasia (United States)

Volumn 15, Issue 4, 2013, Pages 448-453

  Chen, Zhuo ^a   Sun, Jielin ^a   Kim, Seong Tae ^a   Groskopf, Jack ^b   Feng, Junjie ^a   Isaacs, William B ^c   Rittmaster, Roger S ^d   Condreay, Lynn D ^d   Zheng, Siqun Lilly ^a   Xu, Jianfeng ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b Gen Probe Incorporated   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA MICROSEMINOPROTEIN; KALLIKREIN; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN;

ADULT; ALLELE; ARTICLE; DIGITAL RECTAL EXAMINATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER GENE 3; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GENE;

EID: 84875680165     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.122144     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, and Thun MJ (2009). Cancer statistics, 2009. CA Cancer J Clin 59, 225-249.
2. Welch HG and Albertsen PC (2009). Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 101, 1325-1329.
3. Pannek J and Partin AW (1997). Prostate-specific antigen: what's new in 1997. Oncology (Williston Park) 11, 1273-1278; discussion 1279-1282.
4. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, Kiemeney LA, Witjes JA, and Schalken JA (2003). DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44, 8-15; discussion 15-16.
5. Aubin SM, Reid J, Sarno MJ, Blase A, Aussie J, Rittenhouse H, Rittmaster R, Andriole GL, and Groskopf J (2010). PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. J Urol 184, 1947-1952.
6. Ochiai A, Okihara K, Kamoi K, Iwata T, Kawauchi A, Miki T, and Fors Z (2011). Prostate cancer gene 3 urine assay for prostate cancer in Japanese men undergoing prostate biopsy. Int J Urol 18, 200-205.
7. Roobol MJ, Schroder FH, van Leeuwen P, Wolters T, van den Bergh RC, van Leenders GJ, and Hessels D (2010). Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 58, 475-481.
8. Crawford ED, Rove KO, Trabulsi EJ, Qian J, Drewnowska KP, Kaminetsky JC, Huisman TK, Bilowus ML, Freedman SJ, Glover WL Jr, et al. (2012). Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. J Urol 188, 1726-1731.
9. Rittmaster R, Aubin SMJ, Reid J, Sarno MJ, Blase A, Aussie J, Rittenhouse H, Andriole GL, and Groskopf J (2010). Validation of the PCA3 molecular urine test for prediction repeat prostate biopsy outcome in the placebo arm of the dutasterided REDUCE trial. Eur Urol 184, 1947-1952.
10. Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV, Davis JW, Troncoso P, Rittenhouse H, and Babaian RJ (2008). PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 179, 1804-1809; discussion 1809-1810.
11. Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Tindall D, Breed S, Somerville M, and Rittmaster R (2004). Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 172, 1314-1317.
12. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, Brentano S, Mathis J, Pham J, Meyer T, et al. (2006). APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52, 1089-1095.
13. Marchini J, Howie B, Myers S, McVean G, and Donnelly P (2007). A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet 39, 906-913.
14. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, et al. (2007). PLINK: a tool set for wholegenome association and population-based linkage analyses. Am J Hum Genet 81, 559-575.
15. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, and Reich D (2006). Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38, 904-909.
16. Lilja H and Abrahamsson PA (1988). Three predominant proteins secreted by the human prostate gland. Prostate 12, 29-38.
17. Shukeir N, Arakelian A, Kadhim S, Garde S, and Rabbani SA (2003). Prostate secretory protein PSP-94 decreases tumor growth and hypercalcemia of malignancy in a syngenic in vivo model of prostate cancer. Cancer Res 63, 2072-2078.
18. Vanaja DK, Cheville JC, Iturria SJ, and Young CY (2003). Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res 63, 3877-3882.
19. Whitaker HC, Kote-Jarai Z, Ross-Adams H, Warren AY, Burge J, George A, Bancroft E, Jhavar S, Leongamornlert D, Tymrakiewicz M, et al. (2010). The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. PLoS One 5, e13363.
20. Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J, et al. (2008). Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 40, 316-321.
21. Kader AK, Sun J, Isaacs SD, Wiley KE, Yan G, Kim ST, Fedor H, DeMarzo AM, Epstein JI, Walsh PC, et al. (2009). Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate 69, 1195-1205.
22. Lou H, Yeager M, Li H, Bosquet JG, Hayes RB, Orr N, Yu K, Hutchinson A, Jacobs KB, Kraft P, et al. (2009). Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility. Proc Natl Acad Sci USA 106, 7933-7938.
23. Liu F, Hsing AW, Wang X, Shao Q, Qi J, Ye Y, Wang Z, Chen H, Gao X, Wang G, et al. (2011). Systematic confirmation study of reported prostate cancer risk-associated single nucleotide polymorphisms in Chinese men. Cancer Sci 102, 1916-1920.
24. Lu Y, Zhang Z, Yu H, Zheng SL, Isaacs WB, Xu J, and Sun J (2011). Functional annotation of risk loci identified through genome-wide association studies for prostate cancer. Prostate 71, 955-963.
25. Biancolella M, Valentini A, Minella D, Vecchione L, D'Amico F, Chillemi G, Gravina P, Bueno S, Prosperini G, Desideri A, et al. (2007). Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines. Invest New Drugs 25, 491-497.
26. Williams SA, Xu Y, De Marzo AM, Isaacs JT, and Denmeade SR (2010). Prostatespecific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate-targeted PSA/KLK2 double transgenic mice. Prostate 70, 788-796.
27. Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Young CY, Klee GG, Tindall DJ, and Bostwick DG (1997). Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology 49, 857-862.
28. Lintula S, Stenman J, Bjartell A, Nordling S, and Stenman UH (2005). Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue. Prostate 63, 324-329.
29. Becker C, Piironen T, Pettersson K, Bjork T, Wojno KJ, Oesterling JE, and Lilja H (2000). Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum. J Urol 163, 311-316.
30. Nam RK, Zhang WW, Trachtenberg J, Diamandis E, Toi A, Emami M, Ho M, Sweet J, Evans A, Jewett MA, et al. (2003). Single nucleotide polymorphism of the human kallikrein-2 gene highly correlates with serumhuman kallikrein-2 levels and in combination enhances prostate cancer detection. J Clin Oncol 21, 2312-2319.
31. Nam RK, Zhang WW, Klotz LH, Trachtenberg J, Jewett MA, Sweet J, Toi A, Teahan S, Venkateswaran V, Sugar L, et al. (2006). Variants of the hK2 protein gene (KLK2) are associated with serum hK2 levels and predict the presence of prostate cancer at biopsy. Clin Cancer Res 12, 6452-6458.